-
1.发明授权THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS 有权THIADIAZOLDIOXIDE和THIADIAZOLOXIDE AS趋化因子受体CC和配体
公开(公告)号：EP1551818B1
公开(公告)日：2009-02-04
申请号：EP03781311.0
申请日：2003-10-07
发明人： TAVERAS, Arthur, G. , CHAO, Jianhua , BIJU, Purakkattle, J. , YU, Younong , FINE, Jay, S. , HIPKIN, William , AKI, Cynthia, J. , MERRITT, J., Robert , LI, Ge , BALDWIN, John, J. , LAI, Gaifa , WU, Minglang , HECKER, Evan, A.
IPC分类号： C07D285/10 , C07D417/12 , C07D417/14 , A61K31/433 , A61K31/4436
CPC分类号： C07D285/10 , C07D417/02 , C07D417/12 , C07D417/14
摘要： Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).
-
2.发明公开CHOLESTEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF AUTOIMMUNE DISORDERS 审中-公开胆固醇抑制剂录音自身免疫性疾病的治疗
公开(公告)号：EP1560579A1
公开(公告)日：2005-08-10
申请号：EP03768611.0
申请日：2003-11-04
申请人： SCHERING CORPORATION
IPC分类号： A61K31/397 , A61P37/00
CPC分类号： A61K45/06 , A61K31/366 , A61K31/397 , A61K31/40 , A61K2300/00
摘要： The present invention provides methods for treating or preventing an autoimmune disorder and associated conditions by administering at least one sterol absorption inhibitor and compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor; and (b) at least one autoimmune disorder treatment which can be useful for preventing or treating an autoimmune disorder and associated conditions.
-
公开(公告)号：EP0912571B1
公开(公告)日：2004-08-04
申请号：EP97932142.9
申请日：1997-06-18
申请人： SCHERING CORPORATION
发明人： SOLOMON, Daniel, M. , GRACE, Michael, J. , FINE, Jay, S. , BOBER, Loretta, A. , SHERLOCK, Margaret, H.
IPC分类号： C07D471/04
CPC分类号： C07D471/04
摘要： Compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein E, Q, T, U, V, L, Z, X, W, M, Y and Y' are as set forth herein, are described. These compounds are useful as agents in the treatment of allergy, inflammation, autoimmune diseases, B-cell lymphomas, tumors, and the after effects of bone marrow transplantation.
-
公开(公告)号：EP1562582A1
公开(公告)日：2005-08-17
申请号：EP03768596.3
申请日：2003-11-04
申请人： SCHERING CORPORATION
发明人： FINE, Jay, S. , PARKER, Eric, McFee
IPC分类号： A61K31/397 , A61P25/00
CPC分类号： A61K45/06 , A61K31/366 , A61K31/397 , A61K31/40 , A61K2300/00
摘要： The present invention provides methods for treating demyelination and associated conditions by administering at least one sterol absorption inhibitor and compositions, therapeutic combinations and methods including : (a) at least one sterol absorption inhibitor; and (b) at least one demyelination treatment which can be useful for preventing or treating demyelination and associated conditions, such as multiple sclerosis.
-
公开(公告)号：EP1485089A1
公开(公告)日：2004-12-15
申请号：EP03716685.7
申请日：2003-03-17
申请人： SCHERING CORPORATION
发明人： TAVERAS, Arthur, G. , BILLAH, Motasim , LUNDELL, Daniel , KREUTNER, William , JAKWAY, James , FINE, Jay, S. , BOBER, Loretta, A. , CHAO, Jianhua , BIJU, Purakkattle , YU, Younong
IPC分类号： A61K31/422 , A61K31/4402 , A61K31/381 , A61P1/00 , A61P3/00 , A61P7/00 , A61P9/00 , A61P11/00 , A61P17/00 , A61P19/00 , A61P19/10 , A61P25/00 , A61P27/00 , A61P29/00 , A61P35/00
CPC分类号： A61K45/06
摘要： 88thods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula (Chemical formula should be inserted here as it appears on abstract in paper form) ,or pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).
-
6.发明公开METHOD OF TREATING CXCR3 MEDIATED DISEASES USING HETEROCYCLIC SUBSTITUTED PIPERAZINES 审中-公开了治疗CXCR3介导的疾病的取代的杂环哌嗪
公开(公告)号：EP2185154A2
公开(公告)日：2010-05-19
申请号：EP08794839.4
申请日：2008-07-29
发明人： FINE, Jay, S. , KIM, Seong, Heon , ANILKUMAR, Gopinadhan, N. , WONG, Michael, K. C. , ZENG, Qingbei , ROSENBLUM, Stuart, B. , KOZLOWSKI, Joseph, A. , SHAO, Yuefei , MCGUINNESS, Brian, F. , HOBBS,, Douglas, W.
IPC分类号： A61K31/497 , A61P11/00 , A61P11/06 , A61P17/00 , A61P17/14 , A61P19/02 , A61P29/00 , A61P37/00 , A61P37/06 , A61K45/06
CPC分类号： A61K31/497 , A61K45/06 , A61K2300/00
摘要： The present application discloses a method of treating a CXCR3 chemokine receptor mediated disease selected from the group consisting of chronic obstructive pulmonary disease (COPD), asthma, sarcoidosis, systemic lupus erythematosus (SLE), alkylosing spondylitis, fibrotic diseases, pulmonary fibrosis, alopecia areata, scleroderma, lichen planus erythematosus, discoid lupus erythematosus, dermatomyositis, Behcet's disease, Wegener's disease, atopic dermatitis, and graft-vs-host disease (GVHD) in a patient in need of such treatment comprising administering to the patient a therapeutically effective amount of at least one compound having the general structure shown in Formula 1: Formula 1 or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein.
-
公开(公告)号：EP0912571A2
公开(公告)日：1999-05-06
申请号：EP97932142.0
申请日：1997-06-18
申请人： SCHERING CORPORATION
发明人： SOLOMON, Daniel, M. , GRACE, Michael, J. , FINE, Jay, S. , BOBER, Loretta, A. , SHERLOCK, Margaret, H.
CPC分类号： C07D471/04
摘要： Compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein E, Q, T, U, V, L, Z, X, W, M, Y and Y' are as set forth herein, are described. These compounds are useful as agents in the treatment of allergy, inflammation, autoimmune diseases, B-cell lymphomas, tumors, and the after effects of bone marrow transplantation.
-
公开(公告)号：EP1539678A1
公开(公告)日：2005-06-15
申请号：EP03772075.2
申请日：2003-07-30
发明人： TAVERAS, Arthur, G. , AKI, Cynthia, J. , CHAO, Jianping , DWYER, Michael , CHAO, Jianhua , YU, Younong , MERRITT, J., Robert , BIJU, Purakkattle , JAKWAY, James , LAI, Gaifa , WU, Minglang , HECKER, Evan, A. , LUNDELL, Daniel , FINE, Jay, S.
IPC分类号： C07C237/36 , C07C237/44 , C07C311/39 , C07D207/323 , C07D217/24 , C07D307/52 , C07D307/68 , C07D307/81 , C07D307/82 , C07D307/83 , C07D317/46 , C07D319/18 , C07D333/20 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , A61K31/341 , A61K31/36 , A61K31/381
CPC分类号： C07C237/30 , C07C225/20 , C07C237/36 , C07C237/44 , C07C255/59 , C07C311/39 , C07C2601/04 , C07C2601/14 , C07C2602/08 , C07D207/335 , C07D213/74 , C07D217/24 , C07D295/26 , C07D307/38 , C07D307/52 , C07D307/68 , C07D307/81 , C07D307/82 , C07D307/83 , C07D317/46 , C07D319/18 , C07D333/20 , C07D333/36 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14
摘要： Disclosed are novel compounds of the formula (I)or a pharmaceutically acceptable salt or solvate thereof. Also disclosed is the treatment of chemokine-mediated diseases using compounds of the formula (II)
摘要翻译： 公开了可用于治疗趋化因子介导的疾病如急性和慢性炎症性疾病和癌症的具有下式的化合物或其药学上可接受的盐或溶剂合物。
-
9.发明公开METHOD FOR ENHANCING THE ANTIBODY RESPONSE TO SPECIFIC ANTIGENS WITH INTERLEUKIN-10 失效的方式来加快抗体反应的特异性抗原MITINTERLEUKIN-10
公开(公告)号：EP0814829A1
公开(公告)日：1998-01-07
申请号：EP96908750.0
申请日：1996-03-21
申请人： SCHERING CORPORATION
发明人： FINE, Jay, S. , GRACE, Michael, J.
CPC分类号： A61K39/39 , A61K39/092 , A61K2039/55527
摘要： A method for enhancing the immune response of a mammal to a vaccine comprising administering to such a mammal an effective amount of IL-10 in conjunction with the vaccine. A pharmaceutical composition comprised of an effective amount of IL-10, a natural, synthetic or recombinant antigen and a pharmaceutically acceptable carrier.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.02 秒)
